FDA Limits Duration, Usage of Tolvaptan Due to Possible Liver Injury

Print Friendly, PDF & Email
An increased risk of liver injury was observed in recent large clinical trials evaluating tolvaptan for a new use in patients with autosomal dominant polycystic kidney disease (ADPKD)

Read Full Article from Source →

© Copyright 2013 Endoscopy Center. All Rights Reserved Privacy Policy | Site Map

Back to the Top